Amphastar Pharmaceuticals Market Cap 2012-2025 | AMPH

Amphastar Pharmaceuticals market cap history and chart from 2012 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Amphastar Pharmaceuticals market cap as of March 06, 2026 is $1.31B.
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.310B $0.732B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $39.071B 12.09
BridgeBio Pharma (BBIO) United States $14.501B 0.00
Dr Reddy's Laboratories (RDY) India $11.806B 18.36
Supernus Pharmaceuticals (SUPN) United States $2.915B 23.87
Bausch Health Cos (BHC) Canada $2.222B 1.58
Taysha Gene Therapies (TSHA) United States $1.246B 0.00
Personalis (PSNL) United States $0.729B 0.00
Assembly Biosciences (ASMB) United States $0.422B 0.00
Sol-Gel Technologies (SLGL) Israel $0.187B 0.00
Metagenomi Therapeutics (MGX) United States $0.055B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00